Cibas E S, Melamed M R, Zaman M B, Kimmel M
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Cancer. 1989 Apr 15;63(8):1552-6. doi: 10.1002/1097-0142(19890415)63:8<1552::aid-cncr2820630817>3.0.co;2-f.
Tumor size at resection and flow cytometric (FCM) DNA distribution of 93 pathologically confirmed AJC Stage I adenocarcinomas of lung were compared with survival. All lung cancers had been treated by lobectomy and mediastinal lymph node dissection at this Institution, and the pathology of all cases was reviewed. Median tumor size was 2.5 cm. FCM DNA assays were carried out on the formalin-fixed, paraffin-embedded tumor tissue. Seventy-nine (85%) of the tumors were aneuploid and 14 were diploid. There was no significant difference in survival between patients with diploid and aneuploid tumors. The DNA index, proliferation fraction, and fraction of aneuploid cells also had no effect on survival. However, patients with tumors smaller than 3 cm in diameter had a significantly better prognosis than those with larger tumors. Thus, in Stage I adenocarcinoma of lung, tumor size but not cellular DNA content distinguishes subgroups with favorable versus unfavorable prognosis.
将93例经病理证实的AJC I期肺腺癌患者的切除肿瘤大小和流式细胞术（FCM）DNA分布与生存率进行了比较。所有肺癌均在本机构接受肺叶切除术和纵隔淋巴结清扫术治疗，并对所有病例的病理进行了复查。肿瘤大小中位数为2.5厘米。对福尔马林固定、石蜡包埋的肿瘤组织进行了FCM DNA检测。79例（85%）肿瘤为非整倍体，14例为二倍体。二倍体和非整倍体肿瘤患者的生存率无显著差异。DNA指数、增殖分数和非整倍体细胞分数对生存率也无影响。然而，直径小于3厘米的肿瘤患者的预后明显好于肿瘤较大的患者。因此，在I期肺腺癌中，区分预后良好与不良亚组的是肿瘤大小而非细胞DNA含量。
